Tigecycline use in critically ill older patients: Case reports and critical analysis [5]

Journal of the American Geriatrics Society

Volumn 55, Issue 2, 2007, Pages 312-313

  Curcio, Daniel ^a   Fernández, Francisco ^a   Duret, Fernando ^b  

^a Sanatorio San Jose   (Argentina)

^b Wyeth SA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; INOTROPIC AGENT; PHENYTOIN; TIGECYCLINE;

ACINETOBACTER; ACUTE KIDNEY FAILURE; AGED; ARTIFICIAL VENTILATION; BLOOD TOXICITY; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DIABETES MELLITUS; FEMALE; FEVER; HEMODIALYSIS; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LETTER; LEUKOCYTOSIS; LUNG EDEMA; LUNG LAVAGE; MALE; NEPHROTOXICITY; OXYGEN SATURATION; PUS; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; THORAX RADIOGRAPHY;

ACTINOBACTERIA; AGED; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MINOCYCLINE; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 33846569939     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01056.x     Document Type: Letter

References (9)

1. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357-379.
2. Wyeth Pharmaceutics. Tygacil (Tigecycline) for Injection [Package Insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2005.
3. de Mendonca A, Vincent JL, Suter PM et al. Acute renal failure in the ICU. Risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000;26:915-921.
4. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43(Suppl 2):S89-S94.
5. Troy SM, Muralidharan G, Micalizzi M et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-43]. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003, p 5.
6. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-480.
7. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006;43:518-524.
8. Pasterán F, Rapoport M, Petroni A et al. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 2006;50:3222-3224.
9. Luna C, Aruj P, Niederman M et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006;27:158-164.